Home » Research Summaries » Search Results
Archives: Research Summaries

Journal: Journal of Managed Care & Specialty Pharmacy; December 1, 2022
Author(s): Dean M Wingerchuk, Brian G Weinshenker, Dana McCormick, Sasha Barron, Laura Simone and Larissa Jarzylo
Helping payers and treatment providers to understand and appropriately address the burden posed by NMOSD

Journal: Annals of Indian Academy of Neurology; January 11, 2022
Author(s): Varsha A Patil, Saurabh N Kamat, Jamshed A Lalkak and Bhim Singhal
Effectiveness and safety of rituximab in MS, NMOSD, and MOGAD

Journal: Neurology; August 31, 2022
Author(s): Paula Barreras, Eleni S Vasileiou, Angeliki G Filippatou, Kathryn C Fitzgerald, Michael Levy, Carlos A Pardo, Scott D Newsome, Ellen M Mowry, Peter A Calabresi and Elias S Sotirchos
Long-term effectiveness and safety of Rituximab in NMOSD and MOGAD

Journal: Frontiers in Immunology; August 29, 2023
Author(s): Lekha Pandit, Anitha D’Cunha, Chaithra Malli and Akshatha Sudhir
Comparison of two diagnostic tests for MOGAD in an Indian population

Journal: JAMA Neurology; May 1, 2022
Author(s): John J Chen, Saif Huda, Yael Hacohen, Michael Levy, Itay Lotan, Adi Wilf-Yarkoni, Hadas Stiebel-Kalish, Mark A Hellmann, Elias S Sotirchos, Amanda D Henderson, Sean J Pittock, M Tariq Bhatti, Eric R Eggenberger, Marie Di Nome, Ho Jin Kim, Su-Hyun Kim, Albert Saiz, Friedemann Paul, Russell C Dale, Sudarshini Ramanathan, Jacqueline Palace, Valentina Camera, Maria Isabel Leite, Byron L Lam, Jeffrey L Bennett, Sara Mariotto, Dave Hodge, Bertrand Audoin, Elisabeth Maillart, Romain Deschamps, Julie Pique, Eoin P Flanagan and Romain Marignier
IVIG for relapse prevention in adult MOGAD patients

Journal: Neurology; April 25, 2023
Author(s): Nanthaya Tisavipat, Adi Wilf-Yarkoni, Eoin Flanagan, Vyanka Redenbaugh, Yoel Schwartzmann, Mark Hellmann, Assaf Tolkovsky, Hadas Stiebel-Kalish, Itay Lotan, Michael Levy, Rebecca Salky, Adi Vaknin-Dembinsky, Esther Ganelin-Cohen, Alfonso Lopez, Sean Pittock and John Chen
Long-term outcomes in MOGAD patients not receiving any immunotherapy apart from steroids

Journal: Multiple Sclerosis Journal; July 10, 2023
Author(s): Itay Lotan, John J Chen, Yael Hacohen, Omar Abdel-Mannan, Sara Mariotto, Saif Huda, Emily Gibbons, Adi Wilf-Yarkoni, Mark A Hellmann, Hadas Stiebel-Kalish, Sean J Pittock, Eoin P Flanagan, Negar Molazadeh, Monique Anderson, Rebecca Salky, Gabriela Romanow, Patrick Schindler, Ankelien Solveig Duchow, Friedemann Paul and Michael Levy
Effectiveness of IVIG treatment for acute attacks in MOGAD

Journal: Journal of Neuro-Ophthalmology; September 1, 2022
Author(s): Bart K. Chwalisz and Michael Levy
Acute and long-term treatment of MOGAD

Journal: Neurology and Therapy; November 13, 2021
Author(s): Dean M. Wingerchuk, Ina Zhang, Adrian Kielhorn, Minying Royston, Michael Levy, Kazuo Fujihara, Ichiro Nakashima, Imran Tanvir, Friedemann Paul, and Sean J. Pittock
Comparison of FDA-approved treatments for NMOSD patients

Journal: Neurology; July 14, 2015
Author(s): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik and Brian G. Weinshenker
Diagnostic criteria for NMOSD